Share This Page
Drug Price Trends for NDC 64980-0668
✉ Email this page to a colleague
Average Pharmacy Cost for 64980-0668
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEXILETINE 250 MG CAPSULE | 64980-0668-01 | 0.41714 | EACH | 2025-12-17 |
| MEXILETINE 250 MG CAPSULE | 64980-0668-01 | 0.41009 | EACH | 2025-11-19 |
| MEXILETINE 250 MG CAPSULE | 64980-0668-01 | 0.41658 | EACH | 2025-10-22 |
| MEXILETINE 250 MG CAPSULE | 64980-0668-01 | 0.42393 | EACH | 2025-09-17 |
| MEXILETINE 250 MG CAPSULE | 64980-0668-01 | 0.43968 | EACH | 2025-08-27 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 64980-0668
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 64980-0668
Introduction
The pharmaceutical landscape surrounding NDC 64980-0668 revolves around its current market positioning, competitive dynamics, regulatory environment, and pricing strategies. This in-depth analysis aims to inform stakeholders, investors, and healthcare professionals about market potential, revenue forecasts, and pricing trajectories. NDC 64980-0668 corresponds to Doxorubicin Hydrochloride Liposomal Injection, an oncology product with a significant role in cancer treatment regimens.
Product Overview and Therapeutic Significance
Doxorubicin Hydrochloride Liposomal Injection is an established chemotherapeutic agent designed to improve drug delivery and reduce systemic toxicity. It is primarily indicated for conditions such as metastatic ovarian carcinoma, AIDS-related Kaposi’s sarcoma, and certain types of breast cancer. The liposomal formulation enhances drug accumulation in tumor tissues, potentially increasing efficacy and reducing adverse effects.
Its innovation lies in encapsulating doxorubicin within liposomes, facilitating targeted delivery and offering a competitive edge over traditional formulations. As of its latest FDA approval, this formulation has garnered increased interest in oncology circles, especially given the rising incidence of cancers globally.
Market Dynamics and Competitive Landscape
Global Oncology Market Growth
The oncology pharmaceuticals market is projected to expand at a CAGR of approximately 7% from 2023 to 2030, driven by rising cancer prevalence, advanced diagnostic capabilities, and innovations in targeted therapies [1]. As a niche chemotherapy agent, liposomal doxorubicin is positioned within a growing segment of liposomal and nanotech-based chemotherapeutics.
Competitive Environment
The primary competitors include generic formulations of doxorubicin and other liposomal drugs such as Doxil (doxorubicin hydrochloride liposomal), which has a landmark market presence. However, NDC 64980-0668's specific formulation, dosage, and patent protections may influence its market share trajectory.
Patent expiry timelines for similar products suggest potential generic entry around 2024-2025, pressuring pricing and volumes. Additionally, biosimilar development in oncology broadens the competitive landscape, potentially impacting market share and pricing.
Market Penetration and Usage Patterns
The adoption rate of liposomal doxorubicin still faces barriers, including physician familiarity, cost considerations, and institutional procurement policies. Nevertheless, its clinical benefits position it as a preferred option in select indications, particularly where reduced toxicity is prioritized.
Regulatory Environment and Reimbursement
Regulatory agencies like the FDA have been encouraging innovations in targeted cancer therapy. FDA's approval processes for injectable chemotherapeutics remain stringent but favorable for formulations demonstrating clear clinical benefits [2].
Reimbursement policies significantly influence market penetration. Payor coverage for liposomal formulations tends to be favorable when evidence supports improved outcomes or reduced hospitalization costs owing to adverse effects mitigation. However, high manufacturing costs for liposomal drugs often translate into elevated patient copayments and insurer negotiations over pricing.
Pricing Analysis and Projections
Current Pricing Landscape
In the United States, the price of liposomal doxorubicin formulations ranges broadly:
- Doxil: Approximate wholesale acquisition costs (WAC) of $3,000 per 50 mg vial
- Generic alternatives: Prices typically lower, around $1,500-$2,000 per vial
NDC 64980-0668's pricing strategy depends on several factors, including patent status, formulation differences, and market positioning. Given the premium nature of liposomal formulations, initial pricing is anticipated to sit at or slightly above the comparable branded price point, particularly if it offers differentiating clinical benefits.
Price Evolution over the Next 5 Years
Factors influencing future pricing include:
- Patent landscape: Patent protections can sustain premium pricing until expiration, projected around 2024–2026.
- Generic entry: Once generics enter, prices could drop by 30-50%, aligning with typical generic price reductions.
- Manufacturing advancements: Innovations reducing production costs may enable competitive pricing, promoting wider access.
- Market demand and reimbursement changes: Enhanced payer acceptance could support sustained or increased pricing for formulary inclusion.
Projected Price Range (2023-2028):
| Year | Estimated Price per Vial | Notes |
|---|---|---|
| 2023 | $3,000 - $3,500 | Current or premium positioning. |
| 2024 | $2,500 - $3,000 | Patent expiry approaches; generics enter. |
| 2025 | $2,000 - $2,500 | Increased generic presence; price competition intensifies. |
| 2026 | $1,500 - $2,000 | Market normalization post-patent. |
| 2027 | $1,200 - $1,800 | Further commoditization and market saturation. |
Market Entry and Revenue Projections
Revenue forecasts hinge on:
- Market penetration rate: Estimating adoption within target oncology indications.
- Pricing strategies: Premium vs generic pricing impacts.
- Market volume: Incidence rates of targeted cancers.
Assuming a conservative adoption rate of 10% of targeted oncology patients in the U.S., with an estimated target population of 1 million patients annually (for relevant indications), potential annual sales could range from $150 million to $300 million within 3-5 years post-market entry, depending on pricing and market share.
Risks and Opportunities
Risks:
- Patent expiration and generic competition could erode margins.
- Regulatory hurdles may delay approvals or restrict indications.
- Pricing pressure from payers and healthcare providers.
- Market saturation with existing liposomal formulations.
Opportunities:
- Expanding indications in emerging cancer therapies.
- Partnerships and licensing agreements for expanded distribution.
- Cost reduction through manufacturing innovations.
- Enhanced clinical data supporting broader adoption and premium pricing.
Key Takeaways
- The market for NDC 64980-0668 is poised for growth, driven by the expanding oncology drug market and clinical advantages of liposomal formulations.
- Price projections suggest a downward trend post-patent expiration, with potential for premium pricing during initial market entry based on clinical benefits.
- Entry hurdles include patent protections, manufacturing costs, and competitive pressures, but opportunities exist through expanded indications and strategic partnerships.
- Stakeholders should monitor regulatory changes and payer policies as these significantly influence pricing and market access.
- Investment in clinical studies demonstrating cost-effectiveness could support sustained premium pricing and market share.
FAQs
1. What are the primary indications for NDC 64980-0668?
It is primarily indicated for metastatic ovarian carcinoma, AIDS-related Kaposi’s sarcoma, and certain breast cancers, where liposomal doxorubicin offers improved toxicity profiles.
2. When is patent expiration anticipated, and how will it influence pricing?
Patents are projected to expire around 2024-2026. Post-expiration, generic versions are expected to enter the market, leading to significant price reductions.
3. How does the efficacy of liposomal doxorubicin compare to traditional formulations?
Clinical studies demonstrate that liposomal doxorubicin maintains comparable efficacy while reducing systemic toxicity, particularly cardiotoxicity, relative to conventional doxorubicin.
4. What are the key factors influencing future pricing trajectories?
Patent status, market competition, manufacturing costs, clinical benefits, and reimbursement policies are decisive factors.
5. What market segments should stakeholders focus on for growth?
Oncology indications with high unmet needs, institutional markets favoring reduced toxicity, and regions with increasing cancer prevalence present significant opportunities.
Sources
[1] MarketsandMarkets. "Oncology Drugs Market By Therapy, By Indication, By Region - Global Forecast to 2030", 2022.
[2] U.S. Food and Drug Administration. "Guidance for Industry: Oncology Drug Approvals and Labeling", 2021.
More… ↓
